

MOPA References

Below are selected references highlighting the history of the MOPA and various applications of the assay.

MOPA History

Nahm MH, Briles DE, Yu X. Development of a multi-specificity opsonophagocytic killing assay. Vaccine. 2000 Jun 1;18(24):2768-71. doi: 10.1016/s0264-410x(00)00044-x. PMID: 10781864.

Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol. 2003 Jul;10(4):616-21. doi: 10.1128/cdli.10.4.616-621.2003. PMID: 12853394; PMCID: PMC164251.

Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006 Sep;13(9):1004-9. doi: 10.1128/CVI.00112-06. PMID: 16960111; PMCID: PMC1563573.

Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol. 2012 Jun;19(6):835-41. doi: 10.1128/CVI.00086-12. Epub 2012 Apr 18. PMID: 22518015; PMCID: PMC3370448.

MOPA Applications

Sobanjo-ter Meulen A, Vesikari T, Malacaman EA, Shapiro SA, Dallas MJ, Hoover PA, McFetridge R, Stek JE, Marchese RD, Hartzel J, Watson WJ, Musey LK. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. *Pediatr Infect Dis J.* 2015 Feb;34(2):186-94. doi: 10.1097/INF.0000000000000516. PMID: 25741971.

McFetridge R, Meulen AS, Folkerth SD, Hoekstra JA, Dallas M, Hoover PA, Marchese RD, Zacholski DM, Watson WJ, Stek JE, Hartzel JS, Musey LK. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults. *Vaccine.* 2015 Jun 4;33(24):2793-9. doi: 10.1016/j.vaccine.2015.04.025. Epub 2015 Apr 23. PMID: 25913828.

Jackson LA, El Sahly HM, George S, Winokur P, Edwards K, Brady RC, Roupheal N, Keitel WA, Mulligan MJ, Burton RL, Nakamura A, Ferreria J, Nahm MH. Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. *Vaccine.* 2018 Jan 29;36(5):606-614. doi: 10.1016/j.vaccine.2017.12.061. Epub 2017 Dec 24. PMID: 29279281; PMCID: PMC5777223.

Greenberg D, Hoover PA, Vesikari T, Peltier C, Hurley DC, McFetridge RD, Dallas M, Hartzel J, Marchese RD, Collier BG, Stek JE, Abeygunawardana C, Winters MA, MacNair JE, Pujar NS, Musey L. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. *Vaccine.* 2018 Oct 29;36(45):6883-6891. doi: 10.1016/j.vaccine.2018.02.113. Epub 2018 Sep 21. PMID: 30244873 Winthrop KL, Bingham CO 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, Kartman CE. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy. *Arthritis Res Ther.* 2019 Apr 18;21(1):102. doi: 10.1186/s13075-019-1883-1. PMID: 30999933; PMCID: PMC6471863.

Sterrett S, Peng BJ, Burton RL, LaFon DC, Westfall AO, Singh S, Pride M, Anderson AS, Ippolito GC, Schroeder HW Jr, Nahm MH, Krishna Prasad A, Goepfert P, Bansal A. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. *Vaccine.* 2020 Feb 11;38(7):1778-1786. doi: 10.1016/j.vaccine.2019.12.023. Epub 2020 Jan 3. PMID: 31911030; PMCID: PMC8040292.

LaFon D, Kim YI, Burton R, Dransfield M, Nahm M. Pneumococcal Antibody Function for Immunologic Evaluation: Normal Results in Older Adults, and a Novel Analytical Model for Vaccine Response. *J Clin Immunol.* 2021 Nov;41(8):1964-1968. doi: 10.1007/s10875-021-01126-z. Epub 2021 Aug 30. PMID: 34462839; PMCID: PMC8605991.